SEBI Issues Administrative Warning to Neuland Laboratories Over Insider Trading Violation Jun 17, 2025
More news about Neuland Laboratories
17May 25
Neuland Laboratories Stock Plunges 7% as Q4 Profit Nosedives 59%
Neuland Laboratories experienced a significant stock price decline of nearly 7% following disappointing Q4 FY2025 results. The company reported a 59% drop in profit after tax, with revenue decreasing by 13.99% year-over-year. Net profit fell by 58.88%, and EPS dropped from Rs 52.66 to Rs 21.67. The decline is attributed to increased operating costs and reduced sales volumes. Despite providing strong future guidance, investor caution persists, as reflected in the continued downward pressure on the stock price.
16May 25
Neuland Laboratories: Shares Drop 11% Despite FY26 Growth Assurance
Neuland Laboratories reported a 59% decrease in Q4 consolidated net profit to ₹278.10 crore, with revenue falling 15% to ₹328.00 crore. The company's shares dropped 11% following the weak results. Despite the downturn, Neuland expects growth to resume in FY26. Goldman Sachs maintains a 'Buy' rating with a ₹14,775.00 target price. The company announced a final dividend of ₹12.00 per equity share.
Neuland Laboratories' Q4 results show a 13.68% year-over-year revenue decrease to ₹3.28 billion. Net profit fell 58.86% to ₹278.10 million, with EBITDA margin contracting to 15.55%. Despite the downturn, the company recommended a final dividend of ₹12.00 per equity share, subject to shareholder approval.